Phase 3 Readout
GLMD: Phase 3 Topline: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study t
June 30, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 30, 2027
- Company
- Galmed Pharmaceuticals Ltd. (GLMD)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month